Brief: Bone Therapeutics H1 Operating Loss For Period Narrows To EUR 4.0 Million

Biosenic SA

07/09/2022 06:13

Sept 7 (Reuters) - Bone Therapeutics SA  BOTHE.BR :
    * HALF YEAR OPERATING LOSS -3.96 MILLION EUR VERSUS -5.72
MILLION
EUR LOSS YEAR AGO
    * BONE THERAPEUTICS ALLOB’S PHASE IIB INTERIM RESULTS
EXPECTED IN
H1 2023
    * REVERSE MERGER BETWEEN BONE THERAPEUTICS AND MEDSENIC WILL
SOON
LEAD TO A NEW COMPANY, BIOSENIC
    * COMBINED GROUP IS EXPECTED TO HAVE A PROFORMA CASH
POSITION OF
AT LEAST EUR 5 MILLION AT CLOSING 
    * BONE THERAPEUTICS ACQUIRES MAJORITY PARTICIPATION IN
MEDSENIC TO
DERISK AND BROADEN ITS THERAPEUTIC PORTFOLIO
    * COMPANY ENDED FIRST SIX MONTHS OF 2022 WITH EUR 3.96
MILLION IN
CASH AND CASH EQUIVALENTS
    * H1 LOSS FOR PERIOD EUR 3.2 MILLION VERSUS LOSS OF EUR 6.1
MILLION YEAR AGO
    * H1 NO REVENUE VERSUS NO REVENUE YEAR AGO

Source text for Eikon:  ID:nGNE77FfMW 
Further company coverage:  BOTHE.BR 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))